Improving outcomes for children and young adults with relapsed B-cell leukemia after CAR T-cell therapy
Optimizing outcomes for children and young adults with relapse of B-cell acute lymphoblastic leukemia after CD19-targeted chimeric antigen receptor T-cell therapy
['FUNDING_CAREER'] · CHILDREN'S HOSP OF PHILADELPHIA · NIH-11012281
This study is looking for ways to help children and young adults with B-cell acute lymphoblastic leukemia who have had a relapse after a specific type of treatment, by testing new treatment strategies and better ways to track their health at the Children's Hospital of Philadelphia.
Quick facts
| Phase | ['FUNDING_CAREER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | CHILDREN'S HOSP OF PHILADELPHIA (nih funded) |
| Locations | 1 site (PHILADELPHIA, UNITED STATES) |
| Trial ID | NIH-11012281 on ClinicalTrials.gov |
What this research studies
This research focuses on enhancing treatment outcomes for children and young adults who experience a relapse of B-cell acute lymphoblastic leukemia after receiving CD19-targeted chimeric antigen receptor T-cell therapy. The project aims to develop and implement early phase clinical trials that utilize advanced epidemiological methods to better understand and improve patient responses to immunotherapy. Patients may benefit from innovative treatment strategies and improved monitoring of their health outcomes through this research. The work will be conducted at the Children's Hospital of Philadelphia, leveraging a multidisciplinary team of experts in pediatric oncology and immunotherapy.
Who could benefit from this research
Good fit: Ideal candidates for this research include children and young adults diagnosed with relapsed B-cell acute lymphoblastic leukemia who have previously undergone CAR T-cell therapy.
Not a fit: Patients who are not diagnosed with B-cell acute lymphoblastic leukemia or who have not undergone CAR T-cell therapy may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options and improved survival rates for young patients with relapsed B-cell leukemia.
How similar studies have performed: Previous research has shown promising results with CAR T-cell therapy in treating B-cell malignancies, indicating a strong potential for success in this area.
Where this research is happening
PHILADELPHIA, UNITED STATES
- CHILDREN'S HOSP OF PHILADELPHIA — PHILADELPHIA, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MYERS, REGINA M — CHILDREN'S HOSP OF PHILADELPHIA
- Study coordinator: MYERS, REGINA M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: anti-cancer immunotherapy, anticancer immunotherapy